Table 2.
The association between use of different antiplatelet agents and cardiovascular outcomes using an extended cox model.
| Outcome | Events (n) | Nonadjusted model | Model I | Model 2 | ||||
|---|---|---|---|---|---|---|---|---|
| Ticagrelor (n = 108) | Clopidogrel (n = 168) | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Primary end point (composite of CV death, MI and stroke) | 39 (36.1) | 69 (41.1) | 0.83 (0.56∼1.23) | 0.353 | 0.81 (0.50∼1.28) | 0.378 | 0.78 (0.46∼1.33) | 0.367 |
| Death from any cause | 21 (19.4) | 38 (22.6) | 0.83 (0.45∼1.55) | 0.563 | 0.86 (0.47∼1.61) | 0.645 | 0.86 (0.38∼1.89) | 0.708 |
| Cardiovascular death | 15 (13.9) | 30 (17.9) | 0.72 (0.35∼1.46) | 0.356 | 0.73 (0.36∼1.49) | 0.385 | 0.80 (0.35∼2.12) | 0.521 |
| Myocardial infarction | 10 (9.3) | 23 (13.7) | 0.59 (0.25∼1.4) | 0.231 | 0.59 (0.25∼1.4) | 0.233 | 0.72 (0.31∼2.36) | 0.485 |
| Ischemic stroke | 8 (7.4) | 13 (7.7) | 0.91 (0.34∼2.46) | 0.852 | 0.94 (0.35∼2.57) | 0.909 | 0.46 (0.24∼3.07) | 0.172 |